Clear Street LLC Discloses New 12.8% Stake in Ernexa Therapeutics Inc. (ERNA)

On May 14, 2026, Clear Street LLC filed a Schedule 13G with the SEC, disclosing a significant new ownership position in Ernexa Therapeutics Inc. (ERNA). The filing indicates that as of the event date on May 5, 2026, Clear Street LLC beneficially owns 149,499 shares of common stock, representing a 12.8% ownership stake in the company. This represents a substantial increase from a previous holding of zero shares, establishing the filer as a major shareholder. The reporting person, a New York-based limited liability company, reported sole voting power over all 149,499 shares. The filing was made pursuant to Rule 13d-1(d) and was signed by John DiBacco, Head of Markets Trading. The issuer, Ernexa Therapeutics Inc., is headquartered in Cambridge, Massachusetts. This move by Clear Street LLC highlights a significant new institutional interest in the biotechnology firm.